Any myostatin inhibitor FDA approved by 2027
4
Ṁ100Ṁ117Dec 31
63%
chance
1H
6H
1D
1W
1M
ALL
This market predicts whether any myostatin inhibitor will receive regulatory approval for any condition by December 31, 2026. Myostatin inhibitors are being developed to treat conditions like muscular dystrophy and obesity. Notable candidates include Regeneron's trevogrumab and Eli Lilly's bimagrumab. Approval status can be verified through official regulatory agency announcements, such as those from the FDA (https://www.fda.gov/).
This question is managed and resolved by Manifold.
Market context
Get 
1,000 to start trading!
1,000People are also trading
Related questions
Will Retatrutide (new obesity drug) be FDA approved by the end of 2026?
41% chance
Will I get follistatin gene therapy by EOY 2026?
26% chance
Will FDA approve any mRNA vaccine against mesothelioma before 2028?
26% chance
Will FDA approve any mRNA vaccine against stomach adenocarcinoma before 2028?
30% chance
Which of these protein targets will have at least one new drug targeting them receive FDA approval between 2025 and 2030
Will FDA approve any mRNA vaccine against pancreatic adenocarcinoma before 2028?
19% chance
Will FDA approve any mRNA vaccine against prostate adenocarcinoma before 2028?
41% chance
Will FDA approve any mRNA vaccine against esophageal adenocarcinoma before 2028?
33% chance
Will a novel therapeutic/device which confers a survival benefit for glioblastoma be FDA approved by EOY 2028?
51% chance
Will a senolytic drug be used clinically for any purpose by the end of 2028?
50% chance